Diseased PBMC and BMMC samples are occasionally collected at a different date from the initial sample utilized to establish blast percentages. Therefore, DLS is unable to guarantee blast percentages in diseased samples. However, for AML and multiple myeloma BMMCs, DLS performs flow cytometry following cryopreservation to characterize blast percentages, and these results are available to aid in sample selection.
DMDG Open Meeting 2024
Ron Cooke Hub, University of York 133 Deramore Ln, York, United KingdomJoin Discovery Life Sciences at DMDG Open Meeting 2024 September